



### Laboratory Results

	Name: Patient, Patient		Patient ID#: 007008	
	Phone:	Gender:	Birth:	Age:
넕	864-123-4567 File ID:	Male	12/2/1987	32
atie	File ID:	Fasting Statu	s: Unknown	

	Collection Time: 2:02 PM	Specimen ID: 1460324
_		
ē	Collection Date:	Report Type:
.≒	4/13/2020	Complete
ĕ	Received Date:	Report Date:
Sp	4/13/2020	4/13/2020

9.0	_	
Ш		Doctor:
		Test,Testing
	Doctor	,

# SARS Covid 2 IgG/IgM

Test	Current 4/13/20	Reference Range	Units	Previous 4/9/20
SARS Covid 2 IgG	Positive	Negative		
SARS Covid 2 IgM	Negative	Negative		

- IgG and IgM blood-based serology testing may help to identify people who have been exposed to COVID-19 SARS-CoV-2, and may have developed some level of immunity but potentially have mild to no symptoms.
- SARS-CoV-2 IgM antibodies appear early and are generally detectable in blood several days after onset of illness then decrease, while the SARS-CoV-2 IgG antibodies become detectable later following infection.
- Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic assay should be considered to rule out infection in these individuals.
- $\bullet$  Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
- Not for the screening of donated blood.
- This test was developed and its performance characteristics have been determined by Labtech Diagnostics. It has not been cleared or approved by the US Food and Drug Administration.

Interpretation	See Note		

## SARS Covid 2 IgG/IgM

Test	Current 4/13/20	Reference Range	Units	Previous 4/9/20
Test Result	S	CLi	nical	
Significance				
RT-qPCR IgM	IgG			
+ -	_	Patient	may be	in the
window period	of infe	ction.	-	
+ +	-	Patient	may be	in the
early stage of	f infect:	ion.	-	
+ +	+	Patient	is in	the
active phase	of infec	tion.		
+ -	+	Patient	may be	in the
late or recur	rent sta	ge of infe	ction.	
- +	_	Patient	may be	in the
early stage of	f infect:	ion. RT-qP	CR resu	lt may
be false-Nega	tive.	-		_
	+	Patient	may ha	ve had a
past infection	n, and ha	as recovere	ed.	
- +	+	Patient	may be	in the
recovery stage			_	
result may be				1





### Laboratory Results

	Name: Bond, Jannette		Patient ID#: 007	
	Phone:	Gender:	Birth:	Age:
뉥	864-353-9445 File ID:	Male	12/2/1987	32
atie	File ID:	Fasting Status: Unknown		

D:
e:
<u> </u>
e:
0
: e:

	Doctor:
	Lis , Testing
5	,
	,

## SARS Covid 2 IgG/IgM

Test	Current	Reference	Units	Previous
TESL	4/13/20	Range	Ullits	4/9/20

SARS-CoV-2 IgM antibodies appears early and are mostly positive after 3-5 days of onset. SARS-CoV-2 IgM titers then decrease while the SARS-CoV-2 IgG antibody potency starts to rise. During the recovery phase, the titer of the SARS-CoV-2 IgG antibody may increase four times or more compared to the acute phase.

- Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic assay should be considered to rule out infection in these individuals.
- •Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

Not for the screening of donated blood

When using both the SARS-CoV-2 IgM kit and the SARS-CoV-2 IgG kit, the clinical sensitivity was estimated at 89.89% with a 95% confidence interval of 83.62% to 96.15%. Clinical specificity was estimated at 96.50% with a 95% confidence interval of 93.95% to 99.05%.

This test was developed and its performance characteristics determined by Labtech Diagnostics Laboratories. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA).